Key Details
Price
$18.36Annual ROE
-10.83%Beta
1.80Events Calendar
Next earnings date:
Mar 07, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Mar 07, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Nov 16, 2017Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wednesday, November 20, 2024, at 9:30 am GMT. A webcast and replay of the presentation will be available on the Investor Rela.
Interim results from phase 2 proof-of-concept study, using LUNAR-CF for treatment of patients with Cystic Fibrosis, expected 1st half of 2025. The global Cystic Fibrosis market size is projected to reach $62.57 billion by 2032. Interim results from phase 2 proof-of-concept study, using LUNAR-OTC for treatment of patients with OTC Deficiency, expected 1st half of 2025.
TOKYO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its investment in ARCALIS, Inc. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu; hereinafter referred to as "ARCALIS"). ARCALIS is a joint venture between Axcelead, Inc., which manages a group of world-class pharmaceutical and healthcare platform companie.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joseph Payne - President and CEO Andrew Sassine - CFO Pad Chivukula - CSO & COO Conference Call Participants Lili Nsongo - Leerink Whitney Ijem - Canaccord Genuity Evan Wang - Guggenheim Securities Myles Minter - William Blair Samantha Schaeffer - Cantor Fitzgerald Yale Jen - Laidlaw & Company Yigal Nochomovitz - Citi Operator Good day, everyone, and welcome to today's Arcturus Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move.
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arcturus is close to launching the Kostaive COVID-19 vaccine in Japan, with ongoing work on variant protection and influenza vaccine. The company has been able to consistently derive research revenues, maintaining liquidity and avoiding debt, with potential for significant revenue from vaccine orders. Valuation suggests Arcturus may be undervalued compared to peers, with a revised model showing potential for significant revenue growth by 2026.
FAQ
- What is the primary business of Arcturus Therapeutics Holdings?
- What is the ticker symbol for Arcturus Therapeutics Holdings?
- Does Arcturus Therapeutics Holdings pay dividends?
- What sector is Arcturus Therapeutics Holdings in?
- What industry is Arcturus Therapeutics Holdings in?
- What country is Arcturus Therapeutics Holdings based in?
- When did Arcturus Therapeutics Holdings go public?
- Is Arcturus Therapeutics Holdings in the S&P 500?
- Is Arcturus Therapeutics Holdings in the NASDAQ 100?
- Is Arcturus Therapeutics Holdings in the Dow Jones?
- When was Arcturus Therapeutics Holdings's last earnings report?
- When does Arcturus Therapeutics Holdings report earnings?
- Should I buy Arcturus Therapeutics Holdings stock now?